Ku70 and Rad51 vary in their importance for the repair of doxorubicin-versus etoposide-induced DNA damage

Apoptosis

Volumn 16, Issue 4, 2011, Pages 359-369

  Schonn, Ilona ^a   Hennesen, Jana ^a   Dartsch, Dorothee C ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Cell cycle arrest; Cell death; DNA strand breaks; DNA repair; Doxorubicin; Homologous recombination; Non homologous end joining

Indexed keywords

DOXORUBICIN; ETOPOSIDE; KU ANTIGEN; RAD51 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NUCLEAR; CELL CYCLE; COLONY-FORMING UNITS ASSAY; COMET ASSAY; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DOXORUBICIN; ETOPOSIDE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; RAD51 RECOMBINASE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79955777649     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-010-0564-y     Document Type: Article

References (55)

1. PA Jeggo M Lobrich 2006 Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability DNA Repair (Amst) 5 1192 1198 10.1016/j.dnarep.2006.05.011 10.1016/j.dnarep.2006.05.011 1:CAS:528:DC%2BD28XptFSrt74%3D (Pubitemid 44308466)
2. K Rothkamm M Kuhne PA Jeggo M Lobrich 2001 Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks Cancer Res 61 3886 3893 11358801 1:CAS:528:DC%2BD3MXktVWqs7k%3D (Pubitemid 32720946)
3. Y Zhang JD Rowley 2006 Chromatin structural elements and chromosomal translocations in leukemia DNA Repair (Amst) 5 1282 1297 10.1016/j.dnarep.2006. 05.020 10.1016/j.dnarep.2006.05.020 1:CAS:528:DC%2BD28XptFSrt7c%3D (Pubitemid 44291613)
4. I Schonn J Hennesen DC Dartsch 2010 Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage Apoptosis 15 162 172 10.1007/s10495-009-0440-9 20041303 10.1007/s10495-009-0440-9 1:CAS:528:DC%2BC3cXht12qu7c%3D
5. K Hande 1998 Etoposide: four decades of development of a topoisomerase II inhibitor Eur J Cancer 34 1514 1521 10.1016/S0959-8049(98)00228-7 9893622 10.1016/S0959-8049(98)00228-7 1:CAS:528:DyaK1cXmvVSku7k%3D (Pubitemid 28446331)
6. LF Liu TC Rowe L Yang KM Tewey GL Chen 1983 Cleavage of DNA by mammalian DNA topoisomerase II J Biol Chem 258 15365 15370 6317692 1:CAS:528: DyaL3sXmtVylurw%3D
7. G Capranico M Binaschi M Borgnetto F Zunino M Palumbo 1997 A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons TiPS 18 323 329 9345851 1:CAS:528:DyaK2sXmsF2lsb0%3D (Pubitemid 27404659)
8. M Binaschi G Capranico L Dal Bo F Zunino 1997 Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity Mol Pharmacol 51 1053 1059 9187272 1:CAS:528:DyaK2sXjvFWktrY%3D (Pubitemid 27249139)
9. F Zunino G Capranico 1990 DNA topoisomerase II as the primary target of anti-tumor anthracyclines Anticancer Drug Des 5 307 317 1963303 1:CAS:528:DyaK3MXit1Smt7k%3D
10. DA Gewirtz 1999 A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 57 727 741 10075079 10.1016/S0006-2952(98) 00307-4 1:CAS:528:DyaK1MXhsFeksL8%3D (Pubitemid 29094544)
11. K Coldwell SM Cutts TJ Ognibene PT Henderson DR Phillips 2010 Detection of adriamycin-DNA adducts by accelerator mass spectrometry Methods Mol Biol 613 103 118 10.1007/978-1-60327-418-0-7 19997880 10.1007/978-1-60327-418-0-7 1:CAS:528:DC%2BC3cXos1CrurY%3D
12. H Tapiero G Nguyen-Ba TJ Lampidis 1994 Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells Pathol Biol (Paris) 42 328 337 1:CAS:528:DyaK2cXmsVGnsL0%3D (Pubitemid 24201490)
13. J Blasiak K Widera T Pertynski 2003 Hyperthermia can differentially modulate the repair of doxorubicin-damaged DNA in normal and cancer cells Acta Biochim Pol 50 191 195 12673359 1:CAS:528:DC%2BD3sXjt1Srurc%3D (Pubitemid 37034240)
14. DC Dartsch F Gieseler 2007 Repair of idarubicin-induced DNA damage: a cause of resistance? DNA Repair (Amst) 6 1618 1628 10.1016/j.dnarep.2007.05.007 10.1016/j.dnarep.2007.05.007 1:CAS:528:DC%2BD2sXht1amtb7F (Pubitemid 47600106)
15. F Gieseler V Nussler T Brieden J Kunze S Valsamas 1998 Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death Int J Clin Pharmacol Ther 36 25 28 9476145 1:CAS:528:DyaK1cXkt1KnsA%3D%3D (Pubitemid 28031805)
16. N Maniar A Krishan M Israel TS Samy 1988 Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells Biochem Pharmacol 37 1763 1772 10.1016/0006-2952(88)90440-6 1:CAS:528:DyaL1cXktFKltLg%3D
17. C Zhijian L Xiaoxue L Yezhen C Shijie J Lifen L Jianlin L Deqiang H Jiliang 2010 Impact of 1.8-GHz radiofrequency radiation (RFR) on DNA damage and repair induced by doxorubicin in human B-cell lymphoblastoid cells Mutat Res 695 16 21 10.1016/j.mrgentox.2009.10.001 19833226
18. P D'Arpa C Beardmore L Liu 1990 Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons Cancer Res 50 6919 6924 1698546 (Pubitemid 20361091)
19. JE Haber 2000 Partners and pathways repairing a double-strand break Trends Genet 16 259 264 10827453 10.1016/S0168-9525(00)02022-9 1:CAS:528:DC%2BD3cXjslOnu78%3D (Pubitemid 30332142)
20. G Iliakis 2009 Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence Radiother Oncol 92 310 315 10.1016/j.radonc.2009.06.024 10.1016/j.radonc.2009.06.024 1:CAS:528:DC%2BD1MXhtFajtL7M
21. C Wyman DO Warmerdam R Kanaar 2008 From DNA end chemistry to cell-cycle response: the importance of structure, even when it's broken Mol Cell 30 5 6 10.1016/j.molcel.2008.03.007 18406321 10.1016/j.molcel.2008.03.007 1:CAS:528:DC%2BD1cXkvFegurw%3D (Pubitemid 351470155)
22. JC Connelly DR Leach 2004 Repair of DNA covalently linked to protein Mol Cell 13 307 316 14967139 10.1016/S1097-2765(04)00056-5 1:CAS:528: DC%2BD2cXhs1Cgtrg%3D (Pubitemid 38229804)
23. A Zhang YL Lyu CP Lin N Zhou AM Azarova LM Wood LF Liu 2006 A protease pathway for the repair of topoisomerase II-DNA covalent complexes J Biol Chem 281 35997 36003 10.1074/jbc.M604149200 16973621 10.1074/jbc.M604149200 1:CAS:528:DC%2BD28Xht1ajtrbJ (Pubitemid 46041332)
24. G Capranico KW Kohn Y Pommier 1990 Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin Nucleic Acids Res 18 6611 6619 2174543 10.1093/nar/18.22.6611 1:CAS:528: DyaK3MXjsFGltw%3D%3D
25. Y Pommier G Capranico A Orr KW Kohn 1991 Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide Nucleic Acids Res 19 5973 5980 1658748 10.1093/nar/19.21.5973 1:CAS:528:DyaK38XnsFOqtQ%3D%3D (Pubitemid 21913012)
26. PJ Morin B Vogelstein KW Kinzler 1996 Apoptosis and APC in colorectal tumorigenesis Proc Natl Acad Sci USA 93 7950 7954 8755583 10.1073/pnas.93.15. 7950 1:CAS:528:DyaK28XksFSrtbc%3D (Pubitemid 26277145)
27. G Blandino AJ Levine M Oren 1999 Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene 18 477 485 9927204 10.1038/sj.onc.1202314 1:CAS:528:DyaK1MXhtFOrsbY%3D (Pubitemid 29060623)
28. FL Chang MD Lai 2001 Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells J Urol 166 304 310 11435891 10.1016/S0022-5347(05)66150-2 1:CAS:528:DC%2BD3MXkvFemsL4%3D
29. S Eksborg H-S Strandler F Edsmyr I Näslund P Tahvanainen 1985 Pharmacokinetic study of IV infusions of adriamycin Eur J Clin Pharmacol 28 205 212 3987800 10.1007/BF00609693 1:STN:280:DyaL2M7nvFOgtg%3D%3D (Pubitemid 15143785)
30. G Giaccone S Linn J Welink G Catimel H Stieltjes W Van der Vijgh C Eeltink J Vermorken H Pinedo 1997 A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors Clin Cancer Res 3 2005 2015 9815591 1:CAS:528:DyaK2sXns1OgsL0%3D (Pubitemid 27505127)
31. R Greene J Collins J Jenkins J Speyer C Myers 1983 Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols Cancer Res 43 3417 3421 6850648 1:STN:280:DyaL3s3gs1Kgtw%3D%3D (Pubitemid 13061607)
32. K Mross U Mayer K Hamm K Burk D Hossfeld 1990 Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans Eur J Clin Pharmacol 39 507 513 2076745 10.1007/BF00280945 1:CAS:528:DyaK3MXhslOrs7k%3D
33. P Speth P Linssen E Termond J Boezeman H Wessels C Haanen 1989 In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoetic cell subtypes in humans Drug Metab Dispos 17 98 105 2566478 1:CAS:528:DyaL1MXht1yjs7w%3D (Pubitemid 19058172)
34. G Zhu R Gilchrist N Borley H Chng M Morgan J Marshall R Camplejohn G Muir I Hart 2004 Reduction of TSG101 protein has a negative impact on tumor cell growth Int J Cancer 109 541 547 10.1002/ijc.20014 14991575 10.1002/ijc.20014 1:CAS:528:DC%2BD2cXislCisrs%3D (Pubitemid 38339644)
35. D Dartsch A Schaefer S Boldt W Kolch H Marquardt 2002 Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis Apoptosis 7 537 548 10.1023/A:1020647211557 12370496 10.1023/A:1020647211557 1:CAS:528:DC%2BD38XnvV2lurs%3D (Pubitemid 35334448)
36. AR Collins AA Oscoz G Brunborg I Gaivao L Giovannelli M Kruszewski CC Smith R Stetina 2008 The comet assay: topical issues Mutagenesis 23 143 151 10.1093/mutage/gem051 18283046 10.1093/mutage/gem051 1:CAS:528: DC%2BD1cXlsVGltL8%3D
37. PL Olive JP Banath 2006 The comet assay: a method to measure DNA damage in individual cells Nat Protoc 1 23 29 10.1038/nprot.2006.5 17406208 10.1038/nprot.2006.5 1:CAS:528:DC%2BD28XhtFOitbzI
38. O Bar-On M Shapira DD Hershko 2007 Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells Anticancer Drugs 18 1113 1121 17893511 10.1097/CAD.0b013e3282ef4571 1:CAS:528:DC%2BD2sXhtVOgurrJ (Pubitemid 47480736)
39. SM Lee B Youn CS Kim CS Kim C Kang J Kim 2005 Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways Mol Cells 20 331 338 16404146 1:CAS:528:DC%2BD28XmsFyrtLs%3D
40. SJ Robles PW Buehler A Negrusz GR Adami 1999 Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin Biochem Pharmacol 58 675 685 10413306 10.1016/S0006-2952(99)00127-6 1:CAS:528:DyaK1MXks1Wrsb8%3D (Pubitemid 29296889)
41. CD Venkatakrishnan K Dunsmore H Wong S Roy CK Sen A Wani JL Zweier G Ilangovan 2008 HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest Am J Physiol Heart Circ Physiol 294 H1736 H1744 10.1152/ajpheart.91507.2007 18263706 10.1152/ajpheart.91507.2007 1:CAS:528:DC%2BD1cXkvVylurY%3D (Pubitemid 351490604)
42. HS Kim YS Lee DK Kim 2009 Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death Pharmacology 84 300 309 10.1159/000245937 19829019 10.1159/000245937 1:CAS:528:DC%2BD1MXhtlGjtbfL
43. A Malugin P Kopeckova J Kopecek 2007 Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells J Control Release 124 6 10 17869367 10.1016/j.jconrel.2007.08.016 1:CAS:528:DC%2BD2sXhtlWnsbvL (Pubitemid 350088209)
44. PL Puri S Medaglia L Cimino C Maselli A Germani E De Marzio M Levrero C Balsano 1997 Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes J Cell Biochem 66 27 36 9215525 10.1002/(SICI)1097-4644(19970701)66:1<27::AID- JCB4>3.0.CO;2-# 1:CAS:528:DyaK2sXktl2isLg%3D (Pubitemid 27284094)
45. JP Banath D Klokov SH MacPhail CA Banuelos PL Olive 2010 Residual gammaH2AX foci as an indication of lethal DNA lesions BMC Cancer 10 4 10.1186/1471-2407-10-4 20051134 10.1186/1471-2407-10-4
46. PA Speth RA Raijmakers JB Boezeman PC Linssen TJ de Witte HM Wessels C Haanen 1988 In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells Eur J Cancer Clin Oncol 24 667 674 3383969 10.1016/0277-5379(88)90297-0 1:STN:280: DyaL1c3lsFSisw%3D%3D (Pubitemid 18095571)
47. XP Zhang F Liu Z Cheng W Wang 2009 Cell fate decision mediated by p53 pulses Proc Natl Acad Sci USA 106 12245 12250 10.1073/pnas.0813088106 19617533 10.1073/pnas.0813088106 1:CAS:528:DC%2BD1MXpslGjs7s%3D
48. M Binaschi G Capranico P De Isabella M Mariani R Supino S Tinelli F Zunino 1990 Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors Int J Cancer 45 347 352 2154411 10.1002/ijc. 2910450223 1:CAS:528:DyaK3cXhsFWnsrY%3D (Pubitemid 20061392)
49. S Martensson J Nygren N Osheroff O Hammarsten 2003 Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks Radiat Res 160 291 301 12926987 10.1667/0033-7587(2003)160[0291:AOTDPK]2. 0.CO;2 1:CAS:528:DC%2BD3sXmvFGlu7o%3D (Pubitemid 37052427)
50. A Muslimovic S Nystrom Y Gao O Hammarsten 2009 Numerical analysis of etoposide induced DNA breaks PLoS One 4 e5859 10.1371/journal.pone.0005859 19516899 10.1371/journal.pone.0005859
51. TJ Pohl JA Nickoloff 2008 Rad51-independent interchromosomal double-strand break repair by gene conversion requires Rad52 but not Rad55, Rad57, or Dmc1 Mol Cell Biol 28 897 906 10.1128/MCB.00524-07 18039855 10.1128/MCB.00524-07 1:CAS:528:DC%2BD1cXhsVWqtb0%3D (Pubitemid 351160047)
52. K Bahmed KC Nitiss JL Nitiss 2010 UnTTrapping the ends: a new player in overcoming protein linked DNA damage Cell Res 20 122 123 10.1038/cr.2010.17 20118967 10.1038/cr.2010.17
53. EU Kurz KB Leader DJ Kroll M Clark F Gieseler 2000 Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon J Biol Chem 275 13948 13954 10.1074/jbc.275.18.13948 10788521 10.1074/jbc.275.18.13948 1:CAS:528:DC%2BD3cXjtFyrs7w%3D (Pubitemid 30257472)
54. Y Mao SD Desai CY Ting J Hwang LF Liu 2001 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes J Biol Chem 276 40652 40658 10.1074/jbc.M104009200 11546768 10.1074/jbc.M104009200 1:CAS:528: DC%2BD3MXosVKhtLc%3D
55. L Salmena V Lam J McPherson G Goldenberg 2001 Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression Biochem Pharmacol 61 795 802 11274964 10.1016/S0006-2952(01)00580-9 1:CAS:528:DC%2BD3MXit1Sjtr0%3D (Pubitemid 32245561)